Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.42 |
| ▸ | LIPE | Q05469 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 4/20 | 0.42 |
| ▸ | ACACA | Q13085 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16128019 | 0.87 | TAS2R14 (0.49) | TAS2R14OPRM1OPRD1OPRK1P2RX3 | |
| SCHEMBL8017433 | 0.79 | OPRM1 (0.52) | OPRM1OPRD1OPRK1LOXL2RXRA | |
| SCHEMBL21656511 | 0.75 | MAPT (0.60) | OPRM1OPRD1OPRK1P2RX3RXRA | |
| SCHEMBL17570342 | 0.73 | KMT2A (0.47) | RXRASRD5A2 | |
| SCHEMBL21525575 | 0.73 | CA1 (0.59) | OPRM1OPRD1OPRK1LOXL2RXRA | |
| SCHEMBL21628768 | 0.73 | GRM2 (0.62) | OPRM1OPRD1OPRK1P2RX3GRM2 | |
| SCHEMBL4255729 | 0.72 | RXRA (0.54) | OPRM1OPRD1OPRK1P2RX3RXRA | |
| SCHEMBL26117041 | 0.72 | LOXL2 (0.60) | OPRM1OPRD1OPRK1P2RX3LOXL2 | |
| SCHEMBL30629781 | 0.72 | LOXL2 (0.60) | OPRM1OPRD1OPRK1P2RX3LOXL2 | |
| SCHEMBL21525644 | 0.71 | CA1 (0.48) | OPRM1OPRD1OPRK1LOXL2GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118735-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | GRA VENTURE FUND, LLC | 2018-05-03 | — | — | US | disclosed |
| US-20180118735-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | GRA VENTURE FUND, LLC | 2018-05-03 | — | — | US | disclosed |
| US-9822106-B2 | Inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9822106-B2 | Inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20160068522-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068522-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | TAS2R14 4359/4885OPRM1 3838/4885OPRD1 3054/4885 |
| US-20180118735-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | TAS2R14 4359/4885OPRM1 3838/4885OPRD1 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.